Axovant Sciences (AXON) was founded in 2014 as a wholly-owned subsidiary of Roivant Sciences, Inc. (RSL). AXON is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of dementia including Alzheimer’s Disease (AD), Lewy Body Dementia (LBD) and a subset of LBD known as Dementia with Lewy Bodies (DLB), and Parkinson’s Disease Dementia (PDD). Their near-term focus is to develop their lead product, intepirdine (previously RVT-101), a selective 5-HT6 receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies. Additionally AXON has recently started development on nelotanserin, their second product candidate, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with Lewy body dementia and REM behavior disorder (RBD) in patients with DLB. Longer term AXON plans to develop a broader pipeline of product candidates to address a broad range of cognitive, behavioral, and functional aspects of dementia.